Market Size (2016)
2016
$3.56B
Vertical: HealthcareBase Year: 201811 Sections
Market Size (2016)
2016
$3.56B
Projected (2025)
2025
$13.07B
CAGR (2016–2025)
15.5%
15.5%Key Players
108+
Overview
Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to the body’s need for blood and oxygen. This results in fatigue and shortness of breath and sometimes results in a cough. Due to this, everyday activities such as walking, climbing stairs, or carrying heavy weight becomes very difficult.
Factors such as rising cases of cardiovascular disorders, increasing geriatric population, and the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure are driving the market growth. Additionally, a strong pipeline and product approvals are also driving the market growth. However, serious side-effects hamper the growth of the market.
The Heart Failure Drugs Market market is projected to grow at a CAGR of 15.5% from 2016 to 2025.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansScope of the Study
The scope of the global heart failure drugs market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on type, end user, and region.
Research Objective
To provide a comprehensive analysis of the global heart failure drugs market and its sub-segments, thereby providing a detailed structure of the industry To provide detailed insights into factors driving and restraining the growth of the global heart failure drugs marketTo estimate the market size of the global heart failure drugs market where 2016 to 2017 would be the historic period, 2018 shall be the base year, and 2019 to 2025 will be the forecast period for the studyTo provide region-wise market value analysis for various segments of the global heart failure drugs marketTo provide strategic profiling of key companies (manufacturers and distributors) present across the globe and comprehensively analyze their competitiveness/competitive landscape in this marketTo provide a distribution chain analysis/value chain for the global heart failure drugs market
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThreat of New Entrants
The threat of new entrants is high in the global heart failure drugs market. The threat of new entrants is high due to the strong pipeline and rising recent product launches. Major players such as AstraZeneca, Merck Sharp & Dohme Corp., and Bayer are involved in developing heart failure specific drugs such as AZD4831, Vericiguat, and Neladenoson bialanate and are aiming to launch the products during the forecast period of 2019 to 2025.
Bargaining Power of Suppliers
In the global heart failure drugs market, suppliers are raw materials manufacturers for drug manufacturing companies. The bargaining power of suppliers is low as there is a high number of suppliers in the heart failure drugs market. Additionally, the switching cost is low as no supplier can influence the prices and exercise control in the industry, which makes the bargaining power low.
Threat of Substitutes
The threat of substitutes in the global heart failure drugs market is low to medium because of the presence of surgeries. But, the high adoption of these drugs by physicians and brand loyalty restrict the threat by the substitutes. Also, the low to medium degree of switching costs may minimize the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global heart failure drugs market. The presence of buyers in the market is growing due to the increasing awareness about the different products, along with the rising prevalence of heart failure. Additionally, the presence of providers is also increasing, which makes the bargaining power of buyers moderate due to the low switching costs.
Intensity of Rivalry
The degree of competition in the global heart failure drugs market is low as of now. However, it will witness a high degree of competition in the near future. The restrained degree of product and service differentiation among existing players increases the intensity of rivalry in the market. Heart failure drugs provider companies are trying to provide cost-effective services to make them more affordable. To overcome the competition, drug and device manufacturing players are engaged in developing a process to lower their manufacturing costs.
Market estimates by geography (2025)
InsightEurope leads with $3.98B by 2025, while North America is projected to grow fastest at a 16.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $370.04M | $568.68M | $932.87M | 10.8% | 7% |
| North America | $913.62M | $1.77B | $3.63B | 16.6% | 28% |
| Asia Pacific | $911.20M | $1.73B | $3.49B | 16.1% | 27% |
| Europe | $1.06B | $1.99B | $3.98B | 15.9% | 30% |
| South America | $312.72M | $548.51M | $1.03B | 14.1% | 8% |
| Total | $3.56B | $6.62B | $13.07B | 15.5% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$13.07B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Angiotensin Receptor Neprilysin Inhibitors | $4.59B | 15.5% | 85% |
| Angiotensin Receptor Blockers | $2.58B | 15.5% | 73% |
| Angiotensin-Converting Enzyme Inhibitors | $2.07B | 15.5% | 77% |
| Beta Blockers | $1.75B | 15.5% | 61% |
| Diuretics | $1.29B | 15.5% | 60% |
| Others | $797.05M | 15.5% | 53% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Heart Failure Drugs Market covering market dynamics, competitive landscape, and strategic outlook.
The Heart Failure Drugs Market market is projected to reach $13.07B by 2025, growing at 15.5% CAGR. The Angiotensin Receptor Neprilysin Inhibitors segment holds the largest share.
Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to the body’s need for blood and oxygen. This results in fatigue and shortness of breath and sometimes results in a cough. Due to this, everyday activities such as walking, climbing stairs, or carrying heavy weight becomes very difficult.
Factors such as rising cases of cardiovascular disorders, rising geriatric population, and the constantly changing lifestyle habits (such as unhealthy dietary habits, excessive alcohol consumption, smoking, obesity, and lack of physical activity) which make individuals more susceptible to arrhythmia and heart failure are driving the market growth. Additionally, a strong pipeline and product approvals are also driving the market growth. However, serious side-effects hamper the growth of the market.
Likewise, expanding drugs for heart failure with preserved ejection fraction (HF-PEF) would serve as an opportunity for growth.
The heart failure drugs market has witnessed several product launches and clinical trials by major players, which would drive the growth of the heart failure drugs market. For instance,
AstraZeneca received the US Food and Drug Administration (FDA) approval for Farxiga (dapagliflozin) drug to reduce the risk of hospitalization for heart failure (hHF) in adults with type-2 diabetes (T2D) in October 2019. Ono Pharmaceutical, one of the largest pharmaceutical companies in Japan, launched Coralan (ivabradine hydrochloride), for the treatment of people with chronic heart failure (CHF), in Japan in September 2019.Amgen, in collaboration with Cytokinetics, is developing Omecamtiv mecarbil, a selective cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF).Amgen received the US Food and Drug Administration (FDA) approval in April 2015, for Corlanor (ivabradine), an oral medication indicated to reduce the risk of hospitalization for worsening heart failure in patients.
Over the years, chronic heart failure drugs have proved to be successful in slowing the progression of the disease and in reducing both mortality and morbidity in cases of heart failure with reduced ejection fraction (HF-rEF). However, heart failure with preserved ejection fraction (HFpEF) is left with no approved therapies and lies on treatment with guideline-recommended HF-REF therapies.
According to the National Center for Biotechnology Information, heart failure with preserved ejection fraction (HFpEF) is common and represents approximately 50% of the heart failure (HF) cases and is associated with high morbidity and mortality. A high number of patients affected with HFpEF serves as a lucrative opportunity for pharmaceutical companies such as Novartis, which is currently conducting late-stage trials of the Entresto drug in HFpEF patients.
This huge number of patients affected with HF-PEF, along with major manufacturers such as Novartis conducting clinical trials for heart failure with preserved ejection fraction, is likely to drive the growth global heart failure drugs market. Additionally, it will help in meeting the unmet needs of millions of patients affected with HFpEF.
Despite the growing adoption of heart failure drugs, the side-effects of these drugs are hampering the market growth. Major heart failure drugs are known to cause side-effects that can affect the normal lifestyle. For instance, Entresto can cause fetal harm when administered to a pregnant woman. Pregnant women are advised to consider alternative drug treatment and discontinue Entresto. This drug also causes impaired renal function, hyperkalemia, angioedema, and hypotension.
Digoxin is known to cause nausea or vomiting, blurred or colored vision, and abnormal heart rhythm, which may cause palpitation or fainting. These side-effects are likely to hamper the growth of the heart failure drugs market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 108 companies operating in the Heart Failure Drugs Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
BRISTOL-MYERS SQUIBB COMPANY
Company Headquarters: New York, US Founded: 1887 Workforce: ~28,000 Company Working: Bristol-Myers Squibb Company merged with Squibb in 1989. Bristol-Myers Squibb Company is a leading pharmaceutical company committed to develop and deliver innovative biopharmaceutical products to help patients fight diseases globally. It mainly focuses on six core therapeutic areas such as oncology, musculoskeletal, virology, cardiovascular, metabolomics, and immunology.
AstraZeneca
Company Headquarters: Cambridge, UK Founded: 1999 Workforce: 83,100 Company Working: AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.
Boehringer Ingelheim International GmbH
Company Headquarters: Ingelheim am Rhein, Germany Founded: 1885 Workforce: ~50,370 Company Working: Boehringer Ingelheim International GmbH (Boehringer Ingelheim) has more than 100 years of legacy. Boehringer Ingelheim has three main business units, which include prescription medicine, animal health, and biopharma. The main focus of the company is to cure diseases with the help of its core R&D expertise. It constantly works to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies, and on science itself. Geographically it has its presence in Africa, Asia, Australasia, Europe, North America, and South America.
Merck KGaA
Company Headquarters: Darmstadt, Germany Founded: 1668 Workforce: ~60,348 Company Working: Merck KGaA (Merck) is a pharmaceutical company that offers a varied range of products subgrouped into three segments—healthcare, life sciences, and performance materials. The company delivers innovative health solutions and is dedicated to providing breakthrough solutions and technologies. The company research drugs in the areas of oncology and neurodegenerative as well as autoimmune and inflammatory diseases. It also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for industries such as pharmaceuticals, food, cosmetics, packaging, and coatings. It has expanded its global footprint through several mergers and acquisitions, such as the acquisition of Millipore and Sigma-Aldrich. The company is distributing its products in the following countries: China, India, Japan, Australia, Israel, United Arab Emirates, South Korea, Denmark, Italy, Netherlands, Spain, United Kingdom, Switzerland, Sweden, Argentina, Brazil, Canada, US, New Zealand among others.
Amgen Inc.
Company Overview Company Headquarters: California, US Founded: 1980 Workforce: 20,000+ Company Working: Amgen Inc. (Amgen), a well-known biopharmaceutical company, was founded in 1860. The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutic products. It uses tools such as advanced human genetics to unravel the intricacies of diseases and understand the fundamentals of human biology. It serves its products in major therapeutic areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen operates through one business segment, namely, human therapeutics. It focuses on areas that have high unmet medical needs and leverages its expertise to develop solutions for improving health outcomes and efficiently improve people's lives. It has become one of the leading independent biotechnology companies in the world.
Johnson & Johnson Services Inc.
Company Headquarters: New Jersey, US Founded: 1886 Workforce: ~130,000 Company Working: Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. Ethicon has manufactured surgical sutures and wound closure devices since 1887. Ethicon manufactures sutures, endocutters, breast care products, and energy-based products, like hand instruments, for tissue dissection. In 2016, Ethicon acquired NeuWave Medical, Inc.Johnson & Johnson is the world’s largest and broadly based healthcare company. It engages in the R&D, manufacture, and sale of products in the healthcare field. I Its pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, oncology, cardiovascular and metabolism, and pulmonary hypertension t has more than 130 years of industry experience. The company has a team of 134,000 people at 260 companies in more than 60 countries around the globe.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Heart Failure Drugs Market